This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 17 results found since Jan 2013.
High-Dose Prednisolone for Treatment of Infantile Spasms After Presumed Perinatal Stroke
CONCLUSION: This case suggests high-dose prednisolone could be considered for first-line therapy for children with infantile spasms due to perinatal stroke; further study is needed.
Source: Journal of Neuroscience Nursing - March 11, 2021 Category: Neuroscience Tags: Case Study Source Type: research
Progression of Large Vessel Disease in Patients With Giant Cell Arteritis–Associated Ischemic Stroke: The Role of Vascular Imaging: A Case Series
Conclusions Vascular imaging, especially with color-coded duplex sonography, could play a role in the follow-up of patients with GCA-related IS and identify those patients with higher risk of recurrent stroke.
Source: JCR: Journal of Clinical Rheumatology - December 1, 2021 Category: Rheumatology Tags: Original Articles Source Type: research
A Rare Case of Churg Strauss Syndrome Associated with Cervical Spine and Brain Involvement (P4.037)
CONCLUSIONS:This patient meets four major criteria for diagnosis of CSS ( presence of sinusitis, histologic evidence of eosinophilic vasculitis, peripheral eosinophilia and pulmonary infiltrates). CSS associated with spine vasculitis is a rare but potentially serious clinical entity that may also lead to vascular/granulomatous compressive complications leading to permanent neurological damage. This may be only the second case of spinal cord non-hemorrhagic myelitis associated with CSS.Study Supported by:Disclosure: Dr. Mittal has nothing to disclose. Dr. Acsadi has received personal compensation for activities with Talecri...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mittal, S., Acsadi, A., Cruz, L., Aglio, T., Ek, K., Lakshminarayanan, S., Logee, K. Tags: General Neurology III Source Type: research
Fluctuating Mental Status and Fever of Unknown Origin (P1.030)
Conclusion: Central nervous system involvement as the initial manifestation of microscopic polyangiitis is rare and can result in a challenging clinical picture including recurrent ischemic strokes.Disclosure: Dr. Daniel has nothing to disclose. Dr. Brink has nothing to disclose. Dr. Hosley has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Daniel, A., Brink, J., Hosley, C. Tags: Cerebrovascular Disease and Interventional Neurology: Case Reports Source Type: research
Spinal Cord Infarction as the Initial Presentation of Systemic Lupus Erythematosus (P2.077)
CONCLUSIONS:Aggressive therapy with high dose corticosteroids and intravenous cyclophosphamide followed by oral therapy may be a successful therapeutic approach to spinal cord infarcts secondary to systemic lupus erythematosus. Study Supported by: N/ADisclosure: Dr. Michael has nothing to disclose. Dr. Hayat has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Michael, A., Hayat, G. Tags: Neurological Consequences of Autoimmune Disease Source Type: research
Primary Angiitis of the Central Nervous System (PACNS) Presenting with Intracerebral Hemorrhage (P2.293)
Conclusion: Primary CNS vasculitis should be suspected even in patients presenting initially with intracerebral hemorrhage in association with only moderate headaches.Disclosure: Dr. Alkhalifah has nothing to disclose. Dr. Fayad has received research support from the National Institute of Neurological Disorders and Stroke and St. Jude Medical. Dr. Omojola has nothing to disclose. Dr. Hearth-Holmes has nothing to disclose. Dr. McComb has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Alkhalifah, M., Fayad, P., Omojola, M., Hearth-Holmes, M., McComb, R. Tags: Cerebrovascular Disease and Interventional Neurology: Inflammation and Immunology Source Type: research
An Update of the Mayo Clinic Cohort of Patients With Adult Primary Central Nervous System Vasculitis: Description of 163 Patients
This study is based on a cohort of 163 consecutive patients with PCNSV who were examined at the Mayo Clinic over a 29-year period from 1983 to 2011. The aim of the study was to define the characteristics of these patients, which represents the largest series in adults reported to date. A total of 105 patients were diagnosed by angiographic findings and 58 by biopsy results. The patients diagnosed by biopsy more frequently had at presentation cognitive dysfunction, greater cerebrospinal fluid total protein concentrations, less frequent cerebral infarcts, and more frequent leptomeningeal gadolinium-enhanced lesions on magnet...
Source: Medicine - May 1, 2015 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?
Conclusion The baseline data analysis of this natural history study indicates that the outcomes measures utilized in this study were sensitive to the age related differences in strength and motor function that are characteristic of disease progression boys with DMD; however treatment effects were less likely to be identified. These findings reflect the difficulty inherent in obtaining the statistical power needed to substantiate intervention efficacy in the small, heterogeneous samples sizes that are characteristic of DMD clinical studies. Isokinetic dynamometry revealed variability in the muscles affected, which has been ...
Source: PLOS Currents Muscular Dystrophy - July 8, 2016 Category: Neurology Authors: cbuckon Source Type: research
Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia -- Final Results of a Prospective Phase 2 Study
CONCLUSION:Pomalidomide with prednisone is safe therapy with good anti-anemia activity in patients with MF. It could lead to transfusion independence in one third of patients for a median duration of about 30 months. ClinicalTrials.gov Identifier: NCT00946270.Table 1.DisclosuresDaver: Alexion: Consultancy; ImmunoGen: Consultancy; Pfizer: Research Funding; Karyopharm: Research Funding; Otsuka: Consultancy; Novartis: Consultancy; ARIAD: Research Funding; Incyte: Consultancy; Pfizer: Consultancy; BMS: Research Funding; Sunesis: Research Funding; Daiichi-Sankyo: Research Funding; Sunesis: Consultancy; Kiromic: Research Funding...
Source: Blood - November 21, 2018 Category: Hematology Authors: Masarova, L., Daver, N. G., Kadia, T. M., Pemmaraju, N., Jabbour, E. J., Zhou, L., Pierce, S. A., Cortes, J. E., Kantarjian, H. M., Verstovsek, S. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster I Source Type: research
Deadly Respiratory Distress Mimic
Conclusion It’s important for prehospital providers to be able to differentiate metabolic disturbances in the setting of respiratory distress and not be fooled into thinking tachypnea always has a respiratory cause. The physical exam and adjuncts such as end-tidal capnography can assist in the prehospital diagnosis. A COPD exacerbation generally presents as diminished lung sounds, wheezing on exhalation, and a prolonged expiratory phase. Here, a patient will attempt to compensate for the inflammation and mucus accumulation associated with the destruction and narrowing of peripheral airways and a subsequent lack of availa...
Source: JEMS Special Topics - July 17, 2018 Category: Emergency Medicine Authors: Brenton Faber, PhD, NRP Tags: Airway & Respiratory Exclusive Articles Patient Care Source Type: news
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
Publication date: Available online 25 January 2019Source: The Lancet NeurologyAuthor(s): Gil I Wolfe, Henry J Kaminski, Inmaculada B Aban, Greg Minisman, Hui-Chien Kuo, Alexander Marx, Philipp Ströbel, Claudio Mazia, Joel Oger, J Gabriel Cea, Jeannine M Heckmann, Amelia Evoli, Wilfred Nix, Emma Ciafaloni, Giovanni Antonini, Rawiphan Witoonpanich, John O King, Said R Beydoun, Colin H Chalk, Alexandru C BarboiSummaryBackgroundThe Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX) showed that thymectomy combined with prednisone was superior to prednisone alone in improving clinical sta...
Source: The Lancet Neurology - January 26, 2019 Category: Neurology Source Type: research
Strategies for treatment of childhood primary angiitis of the central nervous system
Conclusion No grade-A evidence exists; however, this review provides recommendations for treatment of cPACNS.
Source: Neurology Neuroimmunology and Neuroinflammation - May 2, 2019 Category: Neurology Authors: Beelen, J., Benseler, S. M., Dropol, A., Ghali, B., Twilt, M. Tags: Autoimmune diseases, Vasculitis, All Pediatric, Pediatric stroke; see Cerebrovascular Disease/ Childhood stroke Views [amp ] Reviews Source Type: research
What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Neuro-Beh çet in a Sub-Saharan Africa Country: a Series of Sixteen Patients in Fann Teaching Hospital, Dakar, Senegal.
[Neuro-Behçet in a Sub-Saharan Africa Country: a Series of Sixteen Patients in Fann Teaching Hospital, Dakar, Senegal]. Bull Soc Pathol Exot. 2019;112(3):137-146 Authors: Gaye NM, Ndiaye-Diop MT, Fall M, Ka M, Fall SAA, Diop AM, Kahwaji J, Cissé-Diallo VMP, Mbaye M, Thioub M, Mbodji AB, Mbaye KA, Diagne R, Bakhoum M, Cissé O, Bâ EHM, Diagne NS, Diop-Sène MS, Basse-Faye AM, Sow AD, Sarr MM, Seck LB, Touré K, Ndiaye M, Diop AG Abstract Neuro-Behçet (NB) African studies are mainly North African, but Sub-Saharan Africa is not to be outdone. Our aim was to describe diagnostic and therapeutic features...
Source: Bulletin de la Societe de Pathologie Exotique - December 13, 2019 Category: Tropical Medicine Tags: Bull Soc Pathol Exot Source Type: research
Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news